Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
Establishes NIDDK Centers of Excellence on Rare Kidney Disease Research with grants and cooperative agreements, authorizing $6 million annually for FY2026–2030. Requires an HHS study on testing, prevention, precision medicine (including APOL1 genetic testing) with an 18‑month report, and authorizes $1 million annually for FY2026–2030.
Funding adequacy: liberals want more; conservatives prefer fiscal limits
Narrow health research and training bill with modest cost likely to attract bipartisan support in the House.
Establishes NIDDK Centers of Excellence on Rare Kidney Disease Research with grants and cooperative agreements, authorizing $6 million annually for FY2026–2030.
Requires an HHS study on testing, prevention, precision medicine (including APOL1 genetic testing) with an 18‑month report, and authorizes $1 million annually for FY2026–2030.
Expands provider education and nephrology fellowships focused on rare kidney disease and disproportionately affected populations.
Modest cost, technocratic focus, and clear implementation paths favor enactment, but requires appropriations and may face debate over APOL1 testing and QALY prohibition.
How solid the drafting looks.
Funding adequacy: liberals want more; conservatives prefer fiscal limits
These are examples from the analysis, not a ranked list of the most-affected groups.
Funding adequacy: liberals want more; conservatives prefer fiscal limits
Generally supportive.
Views the bill as a targeted, equity‑focused investment to improve diagnosis, care, and workforce capacity for rare kidney diseases.
Sees the QALY prohibition as a protection for people with disabilities.
Cautiously favorable.
Values the evidence‑building approach, workforce development, and targeted outreach.
Wants fiscal and implementation guardrails, clear privacy protections for genetic testing, and measurable outcomes for CMS experiments.
Mixed to somewhat skeptical.
Supports medical research and disability protections but worries about new federal spending, expanded federal intervention in clinical practice, and genetic testing implications for insurers and patient privacy.
Favors limiting long‑term federal commitments.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Modest cost, technocratic focus, and clear implementation paths favor enactment, but requires appropriations and may face debate over APOL1 testing and QALY prohibition.
The bill has not accumulated any surfaced votes yet.
Funding adequacy: liberals want more; conservatives prefer fiscal limits
Modest cost, technocratic focus, and clear implementation paths favor enactment, but requires appropriations and may face debate over APOL1…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for New Era of Preventing End-Stage Kidney Disease Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.